+972-54-7299-571
/
Contact Us
Beta-O2 Technologies Ltd. Beta-O2 Technologies Ltd. Beta-O2 Technologies Ltd.
Navigation
  • Company
    • About
    • Management Team
    • BOD
    • Scientific Advisory Board
    • Collaborators
    • Investors
  • Product
    • βAir Bio-artificial Pancreas(BAP)
    • Description
    • Trials
      • Pre-Clinical
      • Clinical Trials
  • Scientific background
    • Type 1 Diabetes
    • Encapsulating the Cells
    • Immune Protection
    • Efficient Oxygenation
    • Applications
  • ßeta-O2 in the news
    • Press Releases
    • Press Coverage
    • Scientific Publications
  • Contact us

Press Releases

Home Press Releases
Encapsulation: An Overview of Competitors.

January 22, 2019

shadow
Global Bio-Artificial Pancreas Market 2019 – Medtronic, Beta-O2 Technologies Ltd, JDRF, Defymed, TypeZero Technologies

May 10, 2019

shadow
Device could help insulin-producing cells live longer after transplant and improve treatment of type 1 diabetes

April 25, 2018

shadow
Practical Cure Project Update: Beta-02 ßAir Bio-Artificial Pancreas

February 23, 2017

shadow
Beta-O2 Names Dr. Yuval Avni CEO.
Sherpa Innoventures joins list of company investors

March, 30, 2015

shadow
Beta-O2’s ßAir Bio-artificial Adrenal Device Shows Potential to Treat Adrenocortical Insufficiency and Other Stress-related Disorders

Feb, 19, 2015

shadow
First Patient Successfully Implanted in Safety/Efficacy Study of Beta-O2’s ßAir Bio-Artificial Pancreas for Type 1 Diabetes

Oct, 21, 2014

shadow
Beta O2 has received a grant from JDRF to conduct a clinical trial of the βAir Bio-Artificial Pancreas as a Potential Cure for Type 1 Diabetes

Sept, 10, 2014

shadow


Tel: +972-54-7299-571

E-mail: amir.lichter@beta-O2.com

Beta-O2 Technologies Ltd. © 2021.